Clinical Trials Logo

Relapsed Cancer clinical trials

View clinical trials related to Relapsed Cancer.

Filter by:

NCT ID: NCT06251076 Not yet recruiting - Multiple Myeloma Clinical Trials

Plan Development for Giving Teclistamab in the Outpatient Setting

Start date: March 4, 2024
Phase: Phase 4
Study type: Interventional

This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.

NCT ID: NCT06024603 Recruiting - Refractory Cancer Clinical Trials

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

NCT ID: NCT06004167 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Start date: February 14, 2024
Phase: N/A
Study type: Interventional

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

NCT ID: NCT05922501 Not yet recruiting - Multiple Myeloma Clinical Trials

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

ISABELA
Start date: June 18, 2024
Phase: Phase 2
Study type: Interventional

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

NCT ID: NCT05852717 Recruiting - Refractory Cancer Clinical Trials

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) on Day 9 or 10 of each cycle of combination therapy. Patients will then undergo radiology imaging for disease assessment. Patients can proceed to autoSCT or CAR T-cell therapy or epcoritamab monotherapy upon completion of Cycle 3 per investigator discretion. The rationale for subjects not proceeding to autoSCT or CAR T-cell therapy will be captured in the eCRFs. Hematopoietic stem cell mobilization and collection will be performed according to institutional standards. Patients who do not undergo autoSCT or CAR T-cell therapy may remain on study treatment and continue epcoritamab monotherapy following completion of Cycle 3. Epcoritamab monotherapy may continue from Cycle 4 to Cycle 9, or until unacceptable toxicity, or disease progression per the Lugano Criteria.

NCT ID: NCT05693831 Recruiting - Cancer Clinical Trials

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports

myCare-102
Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications. The primary objective of this study is to survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™and Cellworks Ventura™ reports in facilitating treatment decisions in pan-cancer patients. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.

NCT ID: NCT05681195 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Start date: September 27, 2023
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.

NCT ID: NCT05662397 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Start date: March 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

NCT ID: NCT05641324 Terminated - Multiple Myeloma Clinical Trials

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

NCT ID: NCT05631574 Recruiting - Colorectal Cancer Clinical Trials

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).